Welcome to our dedicated page for Autolus Therapeutics plc SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autolus Therapeutics plc filings document a foreign-issuer ADS structure and material events for a commercial-stage T cell therapy company. The company’s American Depositary Shares trade on the Nasdaq Global Select Market, with each ADS representing one ordinary share, while the ordinary shares are registered in connection with the ADS listing.
Recent Form 8-K disclosures cover financial results, corporate presentations, AUCATZYL revenue updates, pipeline and manufacturing matters, and a master service agreement for lentiviral vector supply used in CAR-T products. The filings also record operational efficiency costs, changes in the company’s independent registered public accounting firm, internal-control disclosures, executive and compensation matters, governance actions and Regulation FD materials.
Autolus Therapeutics plc (AUTL) reported insider activity by U.S. CCO & Country General Manager Cintia Piccina involving both equity awards and a sale of shares. On September 1, 2026, she completed a derivative transaction relating to 20,000 Restricted Share Units (RSUs), with each RSU representing a contingent right to receive one American Depositary Share (ADS); these RSUs vest in four equal annual installments commencing on September 1, 2026. A related entry records the acquisition of 20,000 ADSs on the same date at $2.35 per ADS following the derivative exercise, and she held 60,000 RSUs afterward. On September 2, 2026, she sold 6,713 ADSs in an open-market or private transaction at $2.336 per ADS, and no Rule 10b5-1 trading plan is reported for these transactions.
Autolus Therapeutics plc (symbol AUTL) discloses that Cintia Piccina has filed a notice under Rule 144 for a proposed sale of up to 6,713 American Depositary Shares through Fidelity Brokerage Services LLC on or about September 2, 2026. The ADSs relate to restricted stock vesting on September 1, 2026, received from the issuer as compensation, and the sale includes an amount needed to cover a tax obligation arising from the settlement of the vested equity award.
Autolus Therapeutics plc (AUTL) received an amended Schedule 13D (Amendment No. 11) from a group of Czech- and Cyprus-based investors led by Renata Kellnerova and affiliated PPF entities. The filing reports that PPF IM Ltd. is now the owner of record of 14,782,275 ordinary shares, representing 5.6% of Autolus’s outstanding ordinary shares, based on 266,162,540 shares outstanding as of August 10, 2026.
The shares were moved in an internal reorganization via an intercompany transfer from PPF Biotech B.V. to PPF IM, completed on August 27, 2026, using PPF IM working capital and priced at the prior-day closing price. The group states that the reorganization did not change the ultimate beneficial ownership or voting/dispositive power over the shares and was not undertaken to change or influence control of Autolus. Other than this internal transfer, the reporting persons disclose no transactions in Autolus shares in the last 60 days.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 15,000,000 Autolus Therapeutics plc American Depositary Shares. This position represents 5.64% of the ADSs outstanding.
The reporting persons have shared power to vote and dispose of all 15,000,000 ADSs and no sole voting or dispositive power. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. Armistice Capital and Mr. Boyd may be deemed to beneficially own the securities held by the Master Fund, while the Master Fund retains the right to receive dividends and sale proceeds.
Autolus Therapeutics plc reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Net product revenue from AUCATZYL for relapsed or refractory B-cell precursor acute lymphoblastic leukemia rose to $45.7 million from $20.9 million a year earlier, with six‑month product revenue of $71.9 million versus $29.9 million. Revenue now reflects sales in both the U.S. and U.K., while the planned EU launch remains on hold and no EU revenue is expected in 2026.
The company recorded a quarterly net loss of $39.1 million and a six‑month net loss of $110.7 million, narrowing year over year but reducing shareholders’ equity to $74.8 million from $178.1 million at December 31, 2025. Operating activities used $90.4 million of cash in the first half. As of June 30, 2026, Autolus held $171.4 million in cash and cash equivalents and $30.2 million in marketable securities, and later received $75 million from a new Perceptive Advisors notes facility, which management expects will fund operations for at least one year.
The balance sheet includes substantial non‑recourse financing obligations: $284.3 million in liabilities related to future royalties and milestones under the Blackstone and BioNTech arrangements, with an imputed interest rate of up to 28.70%. The company is executing a workforce reduction of about 13%, incurring $4.2 million of severance in the first half to reduce ongoing operating expenses while expanding commercialization of AUCATZYL in the U.S. and U.K.
Autolus Therapeutics plc reported strong second-quarter 2026 growth driven by its CD19 CAR T therapy AUCATZYL. Net product revenue was $45.7 million for the quarter, up from $20.9 million a year earlier, and 1H 2026 net product revenue was $71.9 million. Gross margin improved sharply to 55% in Q2 2026 from 6% in Q1 2026, reflecting higher volumes and cost-efficiency initiatives. Full-year 2026 AUCATZYL net product revenue guidance was raised to $140–$150 million from $120–$135 million. Loss from operations narrowed to $43.8 million, with net loss at $39.1 million, or $(0.15) per share. Liquidity remained solid with $201.6 million in cash, cash equivalents and marketable securities at June 30, 2026, and a new five-year, interest-only senior credit facility of up to $250 million, including $75 million funded and an additional $25 million available. A prior 13% workforce reduction is expected to lower annual operating expenses by about $15 million starting in 2027, supporting a stated path toward profitability in the adult r/r B-ALL business while Autolus advances multiple obe-cel trials in lupus, pediatric ALL, multiple sclerosis and amyloidosis.
Autolus Therapeutics raised its full-year 2026 guidance for AUCATZYL net product revenue to $140 million–$150 million, up from $120 million–$135 million. Management reported preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million, with AUCATZYL sales increasing about 70% over Q1 2026 and more than 100% versus Q2 2025. Year-to-date gross margin reached approximately 35% for the first half of 2026, compared with a negative gross margin of about 20% in the second half of 2025.
The company entered into a five-year, interest-only senior credit facility with Perceptive Advisors for up to $250 million in aggregate principal amount. An initial $75 million was funded on July 30, 2026, with an additional $25 million available at Autolus’ option for six months and up to $150 million more in later tranches upon revenue milestones. The facility bears interest at one-month SOFR (with a 3.50% floor) plus 7.25%. Autolus also issued Perceptive a warrant to purchase up to 3.5 million ADSs at an exercise price of $1.9314 per ADS. Based on anticipated AUCATZYL revenues and this financing, the company expects its cash, cash equivalents and marketable securities to fund operations into the second quarter of 2028.
Autolus Therapeutics plc entered into a senior secured notes facility of up to $250.0 million with Perceptive Credit Holdings V, LP. On July 30, 2026 it issued $75.0 million of Tranche 1 Notes, with up to $175.0 million available in three additional tranches: $25.0 million through January 30, 2027 and two $75.0 million tranches contingent on Consolidated Net Revenue levels before July 31, 2028 and January 31, 2030.
The notes mature on July 30, 2031 and bear interest, paid monthly, at 6.75%–7.25% above the greater of one‑month term SOFR or 3.50%, with a possible 4.00% default step‑up. Obligations are guaranteed by key subsidiaries and secured by a first‑priority lien on substantially all assets, and include financial covenants such as maintaining a Minimum Liquidity Amount between $12.5 million and $50.0 million and specified Consolidated Net Revenue levels.
In connection with the financing, Autolus issued Perceptive a warrant for up to 3,500,000 ADSs at an exercise price of $1.9314 per ADS, a 25% premium to the 30‑day volume weighted average price, and will issue additional warrants for up to 2,500,000 ADSs with each of Tranche 3 and Tranche 4. All warrants expire on July 30, 2036, may be exercised on a cashless basis, and benefit from resale registration rights.
Autolus Therapeutics plc director William D. Young received equity-based compensation awards. On June 29, 2026, he was granted options to purchase 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He was also granted 31,667 restricted share units, each representing one American Depositary Share, vesting in a single installment on June 29, 2027. Following these awards, his reported holdings in these instruments match the granted amounts.
Autolus Therapeutics plc director Rao Madduri Ravin received new equity awards in the form of options and restricted share units tied to American Depositary Shares. The grant includes 47,500 share options with a $1.61 exercise price expiring on June 29, 2036, and 31,667 restricted share units. The RSUs vest in a single installment on June 29, 2027, while the options vest in twelve equal monthly installments starting on July 29, 2026. These awards represent compensation-related acquisitions rather than open-market purchases or sales.